Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia

Br J Haematol. 2004 Mar;124(5):618-25. doi: 10.1111/j.1365-2141.2004.04829.x.

Abstract

Neoangiogenesis is an integral component of bone marrow myeloproliferation in patients with myelofibrosis with myeloid metaplasia (MMM). As extramedullary haematopoiesis is a constitutive feature of MMM, we studied spleen neoangiogenesis by a computerized image analysis in MMM patients. Compared with five normal subjects, spleen CD34-staining capillary vascular density (CVD) was 2.1-3.03 times higher than the upper range of normal in six of the 15 (40%) MMM patients. CD8-staining sinusoidal vascular density (SVD) was constantly normal or lesser than normal and was inversely correlated with CVD (R = -0.53; P = 0.04). In MMM patients who did not receive cytoreductive or radiation therapy in the month before splenectomy (n = 9), the CVD was a significant determinant of spleen size (R = 0.88; P = 0.04). In MMM patients, the number of spleen CD34+ haematopoietic stem cells was increased from 1.2 to 98 times the upper limit of normal, and predicted the expansion of CVD (R = 0.57; P = 0.03). A population of cells expressing the CD34+/CD133+/VEGFR-2+ angiopoietic phenotype was present in the blood and spleen of five of seven patients. These results document that neoangiogenesis is an integral component of spleen re-localization of haematopoietic stem cells and suggest a cellular mechanism for spleen neoangiogenesis.

MeSH terms

  • Adult
  • Aged
  • Antigens, CD34 / analysis
  • Capillaries
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neovascularization, Pathologic / blood
  • Neovascularization, Pathologic / complications
  • Neovascularization, Pathologic / pathology*
  • Primary Myelofibrosis / blood
  • Primary Myelofibrosis / complications
  • Primary Myelofibrosis / pathology*
  • Spleen / blood supply*
  • Splenectomy
  • Vascular Endothelial Growth Factor A / blood

Substances

  • Antigens, CD34
  • Vascular Endothelial Growth Factor A